|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jiang C, Chen X, Alattar M, Wei J and Liu
H: MicroRNAs in tumorigenesis, metastasis, diagnosis and prognosis
of gastric cancer. Cancer Gene Ther. 22:291–301. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ajani JA: Chemotherapy for gastric
carcinoma: New and old options. Oncology (Williston Park).
12:44–47. 1998.PubMed/NCBI
|
|
5
|
Tannock IF: Cancer: Resistance through
repopulation. Nature. 517:152–153. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kessler DA, Austin RH and Levine H:
Resistance to chemotherapy: Patient variability and cellular
heterogeneity. Cancer Res. 74:4663–4670. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Judd LM, Bredin K, Kalantzis A, Jenkins
BJ, Ernst M and Giraud AS: STAT3 activation regulates growth,
inflammation, and vascularization in a mouse model of gastric
tumorigenesis. Gastroenterology. 131:1073–1085. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bromberg JF, Wrzeszczynska MH, Devgan G,
Zhao Y, Pestell RG, Albanese C and Darnell JE Jr: Stat3 as an
oncogene. Cell. 98:295–303. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li Y, Rogoff HA, Keates S, Gao Y,
Murikipudi S, Mikule K, Leggett D, Li W, Pardee AB and Li CJ:
Suppression of cancer relapse and metastasis by inhibiting cancer
stemness. Proc Natl Acad Sci USA. 112:1839–1844. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hajimoradi M, Mohammad Hassan Z, Ebrahimi
M, Soleimani M, Bakhshi M, Firouzi J and Samani FS: STAT3 is
overactivated in gastric cancer stem-like cells. Cell J.
17:617–628. 2016.PubMed/NCBI
|
|
11
|
Deng JY, Sun D, Liu XY, Pan Y and Liang H:
STAT-3 correlates with lymph node metastasis and cell survival in
gastric cancer. World J Gastroenterol. 16:5380–5387. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gong W, Wang L, Yao JC, Ajani JA, Wei D,
Aldape KD, Xie K, Sawaya R and Huang S: Expression of activated
signal transducer and activator of transcription 3 predicts
expression of vascular endothelial growth factor in and angiogenic
phenotype of human gastric cancer. Clin Cancer Res. 11:1386–1393.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cafferkey C and Chau I: Novel STAT 3
inhibitors for treating gastric cancer. Expert Opin Investig Drugs.
25:1023–1031. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Furtek SL, Backos DS, Matheson CJ and
Reigan P: Strategies and approaches of targeting STAT3 for cancer
treatment. ACS Chem Biol. 11:308–318. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lai PS, Rosa DA, Magdy Ali A, Gómez-Biagi
RF, Ball DP, Shouksmith AE and Gunning PT: A STAT inhibitor patent
review: Progress since 2011. Expert Opin Ther Pat. 25:1397–1421.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Boutros T, Chevet E and Metrakos P:
Mitogen-activated protein (MAP) kinase/MAP kinase phosphatase
regulation: Roles in cell growth, death, and cancer. Pharmacol Rev.
60:261–310. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Meng X and Zhang S: MAPK cascades in plant
disease resistance signaling. Annu Rev Phytopathol. 51:245–266.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kim EK and Choi EJ: Compromised MAPK
signaling in human diseases: An update. Arch Toxicol. 89:867–882.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Page BD, Fletcher S, Yue P, Li Z, Zhang X,
Sharmeen S, Datti A, Wrana JL, Trudel S, Schimmer AD, et al:
Identification of a non-phosphorylated, cell permeable, small
molecule ligand for the Stat3 SH2 domain. Bioorg Med Chem Lett.
21:5605–5609. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang X, Yue P, Page BD, Li T, Zhao W,
Namanja AT, Paladino D, Zhao J, Chen Y, Gunning PT and Turkson J:
Orally bioavailable small-molecule inhibitor of transcription
factor Stat3 regresses human breast and lung cancer xenografts.
Proc Natl Acad Sci USA. 109:9623–9628. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Resetca D, Haftchenary S, Gunning PT and
Wilson DJ: Changes in signal transducer and activator of
transcription 3 (STAT3) dynamics induced by complexation with
pharmacological inhibitors of Src homology 2 (SH2) domain
dimerization. J Biol Chem. 289:32538–32547. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zheng L, Xu C, Guan Z, Su X, Xu Z, Cao J
and Teng L: Galectin-1 mediates TGF-β-induced transformation from
normal fibroblasts into carcinoma-associated fibroblasts and
promotes tumor progression in gastric cancer. Am J Transl Res.
8:1641–1658. 2016.PubMed/NCBI
|
|
23
|
Luwor RB, Stylli SS and Kaye AH: The role
of Stat3 in glioblastoma multiforme. J Clin Neurosci. 20:907–911.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang X, Yue P, Fletcher S, Zhao W,
Gunning PT and Turkson J: A novel small-molecule disrupts Stat3 SH2
domain-phosphotyrosine interactions and Stat3-dependent tumor
processes. Biochem Pharmacol. 79:1398–1409. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhuang S: Regulation of STAT signaling by
acetylation. Cell Signal. 25:1924–1931. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tong M, Wang J, Jiang N, Pan H and Li D:
Correlation between p-STAT3 overexpression and prognosis in lung
cancer: A systematic review and meta-analysis. PLoS One.
12:e01822822017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yu S, Li G, Wang Z, Wang Z, Chen C, Cai S
and He Y: The prognostic value of pSTAT3 in gastric cancer: A
meta-analysis. J Cancer Res Clin Oncol. 142:649–657. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Aggarwal BB, Sethi G, Ahn KS, Sandur SK,
Pandey MK, Kunnumakkara AB, Sung B and Ichikawa H: Targeting
signal-transducer-and-activator-of-transcription-3 for prevention
and therapy of cancer: Modern target but ancient solution. Ann N Y
Acad Sci. 1091:151–169. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Pan YM, Wang CG, Zhu M, Xing R, Cui JT, Li
WM, Yu DD, Wang SB, Zhu W, Ye YJ, et al: STAT3 signaling drives
EZH2 transcriptional activation and mediates poor prognosis in
gastric cancer. Mol Cancer. 15:792016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gelain A, Mori M, Meneghetti F and Villa
S: Signal transducer and activator of transcription protein 3
(STAT3): An update on its direct inhibitors as promising anticancer
agents. Curr Med Chem. Jul 19–2018.(Epub ahead of print).
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Schust J, Sperl B, Hollis A, Mayer TU and
Berg T: Stattic: A small-molecule inhibitor of STAT3 activation and
dimerization. Chem Biol. 13:1235–1242. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Song H, Wang R, Wang S and Lin J: A
low-molecular-weight compound discovered through virtual database
screening inhibits Stat3 function in breast cancer cells. Proc Natl
Acad Sci USA. 102:4700–4705. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Siddiquee K, Zhang S, Guida WC, Blaskovich
MA, Greedy B, Lawrence HR, Yip ML, Jove R, McLaughlin MM, Lawrence
NJ, et al: Selective chemical probe inhibitor of Stat3, identified
through structure-based virtual screening, induces antitumor
activity. Proc Natl Acad Sci USA. 104:7391–7396. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hu QD, Chen W, Yan TL, Ma T, Chen CL,
Liang C, Zhang Q, Xia XF, Liu H, Zhi X, et al: NSC 74859 enhances
doxorubicin cytotoxicity via inhibition of epithelial-mesenchymal
transition in hepatocellular carcinoma cells. Cancer Lett.
325:207–213. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chen W, Shen X, Xia X, Xu G, Ma T, Bai X
and Liang T: NSC 74859-mediated inhibition of STAT3 enhances the
anti-proliferative activity of cetuximab in hepatocellular
carcinoma. Liver Int. 32:70–77. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lin L, Amin R, Gallicano GI, Glasgow E,
Jogunoori W, Jessup JM, Zasloff M, Marshall JL, Shetty K, Johnson
L, et al: The STAT3 inhibitor NSC 74859 is effective in
hepatocellular cancers with disrupted TGF-beta signaling. Oncogene.
28:961–972. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhang Q, Zhang C, He J, Guo Q, Hu D, Yang
X, Wang J, Kang Y, She R, Wang Z, et al: STAT3 inhibitor stattic
enhances radiosensitivity in esophageal squamous cell carcinoma.
Tumour Biol. 36:2135–2142. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Pan Y, Zhou F, Zhang R and Claret FX:
Stat3 inhibitor Stattic exhibits potent antitumor activity and
induces chemo- and radio-sensitivity in nasopharyngeal carcinoma.
PLoS One. 8:e545652013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ahmad SF, Ansari MA, Nadeem A, Zoheir KMA,
Bakheet SA, Alsaad AMS, Al-Shabanah OA and Attia SM: STA-21, a
STAT-3 inhibitor, attenuates the development and progression of
inflammation in collagen antibody-induced arthritis. Immunobiology.
222:206–217. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Park JS, Kwok SK, Lim MA, Kim EK, Ryu JG,
Kim SM, Oh HJ, Ju JH, Park SH, Kim HY and Cho ML: STA-21, a
promising STAT-3 inhibitor that reciprocally regulates Th17 and
Treg cells, inhibits osteoclastogenesis in mice and humans and
alleviates autoimmune inflammation in an experimental model of
rheumatoid arthritis. Arthritis Rheumatol. 66:918–929. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Takaishi M, Yokogawa M, Miyoshi K,
Nakajima K, DiGiovanni J and Sano S: STA-21, a stat3 inhibitor,
induces differentiation of normal human epidermal keratinocytes and
human keratinocyte derived cell lines. J Invest Dermatol. 130
(Suppl):S97. 2010.
|
|
42
|
Ambrosini G, Adida C and Altieri DC: A
novel anti-apoptosis gene, survivin, expressed in cancer and
lymphoma. Nat Med. 3:917–921. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Baldin V, Lukas J, Marcote MJ, Pagano M
and Draetta G: Cyclin D1 is a nuclear protein required for cell
cycle progression in G1. Genes Dev. 7:812–821. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Burotto M, Chiou VL, Lee JM and Kohn EC:
The MAPK pathway across different malignancies: A new perspective.
Cancer. 120:3446–3456. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Chen F: JNK-induced apoptosis,
compensatory growth, and cancer stem cells. Cancer Res. 72:379–386.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Scuteri A, Galimberti A, Maggioni D,
Ravasi M, Pasini S, Nicolini G, Bossi M, Miloso M, Cavaletti G and
Tredici G: Role of MAPKs in platinum-induced neuronal apoptosis.
Neurotoxicology. 30:312–319. 2009. View Article : Google Scholar : PubMed/NCBI
|
